Genitourinary Cancers | Specialty

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research.

Nivolumab/Cabozantinib Combo Shows Promise in GU Cancers

October 18th 2016

Cabozantinib plus nivolumab demonstrated promising activity in the second-line setting and beyond at all dose levels tested in patients with advanced/refractory genitourinary cancers.

Immunotherapy Emerges as Alternative to Surgery in BCG-Refractory Bladder Cancer

October 18th 2016

Surgical treatment of patients with non-muscle invasive bladder cancer can be considered a curative option, but the associated risk in comorbid patients is leading researchers to further explore the option of immunotherapy.

Expert Assesses Immunotherapy Advances in Kidney Cancer

October 18th 2016

Immunotherapy is at the forefront of the burgeoning treatment landscape in renal cell carincoma, according to David McDermott, MD.

Dr. Albiges on Immunotherapy in Renal Cell Carcinoma

October 18th 2016

Laurence Albiges, MD, ‎medical oncologist, head, Genitourinary Oncology Unit, Gustave Roussy, discusses how immunotherapy has had an impact on the field of renal cell carcinoma (RCC).

Concurrent Chemoradiation, Radical Cystectomy Demonstrate Similar Median OS Rates in Urothelial Cancer

October 14th 2016

In a propensity-matched analysis of a national cancer registry, patients who underwent radical cystectomy or concurrent chemoradiation to treat urothelial cancer demonstrated statistically similar median overall survival rates. Further analysis suggests that the hazard ratios between the two treatments change over time and is hypothesis generating.

Improving Patient Selection Key to Optimizing Novel GU Cancer Treatments

October 13th 2016

As the fields of renal cell carcinoma and bladder cancer continue to dramatically progress with the approval of novel agents—both immune-based and targeted therapies—oncologists need to improve their methods of selecting patients to receive such available therapies.

Dr. Choueiri on CABOSUN Trial Results for RCC

October 13th 2016

Toni K. Choueiri, MD, clinical director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, discusses the results of the phase II CABOSUN trial, which compared cabozantinib (Cabometyx) with sunitinib (Sutent) in the frontline setting of patients with metastatic renal cell carcinoma (RCC).

Frontline Cabozantinib Bests Sunitinib in mRCC

October 11th 2016

Cabozantinib (Cabometyx) reduced the risk of progression or death by 31% compared with sunitinib (Sutent) in the frontline setting for patients with metastatic renal cell carcinoma.

First-Line Pembrolizumab Shows Substantial Activity in Advanced Bladder Cancer

October 10th 2016

Early results from a pre-planned interim analysis in the KEYNOTE-052 phase II trial of first-line pembrolizumab in cisplatin-ineligible patients with metastatic urothelial cancer demonstrated antitumor activity and a favorable response rate.

Adjuvant Sunitinib Extends DFS in High-Risk RCC

October 10th 2016

Adjuvant sunitinib prolonged disease-free survival by 1.2 years compared with placebo following nephrectomy for patients with high-risk clear cell renal cell carcinoma.

Second-Line Nivolumab Data in mUC Show Efficacy as FDA Considers Approval

October 9th 2016

Safety, efficacy, and biomarker results from the phase II CheckMate-275 trial of the PD-1 inhibitor nivolumab (Opdivo) that support FDA and European Medicines Agency applications were reported at the 2016 ESMO Congress.

Targeted Treatments Still King in Kidney Cancer, Novel Combinations on the Horizon

October 4th 2016

In kidney cancer there are three “eras” in the history of treatment advances, said James Hsieh, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center.

Dr. Sweis on Trend Toward Immunotherapy in GU Malignancies

October 3rd 2016

Randy F. Sweis, MD, clinical instructor, University of Chicago Medicine, discusses the trend toward immunotherapy in the field of genitourinary malignancies.

Patient Preference Among Key Considerations in Frontline RCC Therapy

October 3rd 2016

Historically, patients with advanced renal cell carcinoma have had few treatment options, but several targeted agents and one immunotherapy, the checkpoint inhibitor nivolumab, have been approved within the past 5 years, considerably expanding the RCC treatment arsenal. In the frontline setting, targeted agents are often the go-to therapy.

Expert Discusses Immense Impact of Immunotherapy in GU Cancers

September 21st 2016

Elizabeth Plimack, MD, discusses some of the most impressive advancements with immunotherapy agents in the fields of renal cell carcinoma and bladder cancer, as well as remaining questions with the use of these treatments.

EMA Initiates Official Review of Nivolumab in Bladder Cancer

September 20th 2016

The European Medicines Agency has validated a type II variation application for use of nivolumab (Opdivo) as a treatment for patients with locally advanced unresectable or metastatic urothelial carcinoma who have progressed following platinum-based chemotherapy.

EC Approves Lenvatinib/Everolimus Combo for RCC

September 16th 2016

The European Commission has approved lenvatinib (Kisplyx) in combination with everolimus for patients with advanced renal cell carcinoma following 1 prior VEGF-targeted therapy.

Expert Discusses Impact of Atezolizumab in Advanced Bladder Cancer

September 15th 2016

The PD-L1 inhibitor atezolizumab has been found to be non-toxic and has demonstrated a major survival advantage in patients with metastatic urothelial bladder cancer.

EC Approves Cabozantinib for Renal Cell Carcinoma

September 15th 2016

The European Commission has approved cabozantinib for the treatment of patients with advanced renal cell carcinoma after the failure of VEGF-targeted therapy, according to Exelixis and Ipsen, the manufacturers of the multikinase inhibitor.

FDA Panel Votes Against Apaziquone in Bladder Cancer

September 14th 2016

The FDA’s Oncologic Drugs Advisory Committee voted 14-0 against approving apaziquone (EOquin; Qapzola) for intravesical instillation immediately following transurethral resection in patients with non-muscle invasive bladder cancer.